Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shaylee Nystrom

Physician Assistant, Medical Reno, NV Physician Assistant

NPI 1003578204 CMS profile 11268007

5578 Longley Ln, Reno, NV 89511

Open in the dashboard

General payments

$4,251

109 records reported · program years 2021–2025

Research payments

$95

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shaylee Nystrom of Reno, NV is reported in the CMS Open Payments database as having received $4,251 across 109 general payments and $95 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,334 37
2024 General $1,389 33
2023 General $583 18
2022 General $851 18
2021 General $93 3
2021 Research $95 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shaylee Nystrom
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Shaylee Nystrom were reported at $1,334. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Shaylee Nystrom Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $93 $156 $41–$563 $132
2022 $851 $185 $55–$649 $149
2023 $583 $199 $58–$717 $160
2024 $1,389 $206 $62–$740 $164
2025 $1,334 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,219 26 payments
  2. Nevro Corp. $398 8 payments
  3. SI-BONE, Inc. $323 3 payments
  4. Collegium Pharmaceutical, Inc. $285 15 payments
  5. Saluda Medical Americas, Inc. $230 5 payments
  6. AbbVie, Inc. $192 8 payments
  7. Medtronic, Inc. $173 3 payments
  8. MML US, Inc. $160 2 payments
  9. Globus Medical, Inc. $158 7 payments
  10. Bioventus LLC $136 2 payments
  11. Other $979 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,251 109 payments
Products named General payments · program years 2021–2025
  1. Senza Spinal Cord Stimulator $398 8 payments
  2. ETERNA Structural Heart $334 8 payments
  3. XTAMPZA $285 15 payments
  4. PROCLAIM Neuromodulation $236 6 payments
  5. Evoke SCS $230 5 payments
  6. ETERNA Neuromodulation $226 6 payments
  7. ReActiv8 $160 2 payments
  8. PROCLAIM Structural Heart $148 1 payment
  9. INTERSTIM $135 1 payment
  10. Senza Spinal Cord Stimulator $131 6 payments
  11. Other $1,812 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $95 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,697

Median for Physician Assistant: 241

Drug cost

$46,762

Median for Physician Assistant: $4,110

Branded share of claims

33.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 369 $8,929
Xtampza Er Oxycodone Myristate Brand 12 $7,343
Oxycontin Oxycodone Hcl Brand 13 $5,595
Pregabalin Generic 131 $5,503
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 157 $5,490
Gabapentin Generic 242 $3,156
Oxycodone Hcl Generic 112 $2,701
Tizanidine Hcl Generic 127 $1,922
Duloxetine Hcl Generic 67 $1,033
Celecoxib Generic 14 $870

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$24,513

Medicare's payments for the services billed

Medicare patients

114

Average age 71

Services billed

363

78 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 34%
Diabetes 25%
Chronic kidney disease 25%
Osteoporosis 25%
COPD 24%
Ischemic heart disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $122
$122 12 —
UBRELVY
  • AbbVie, Inc. $12
$12 — —
QULIPTA
  • AbbVie, Inc. $12
$12 — —
NURTEC ODT
  • PFIZER INC. $7
$7 — —
ZAVZPRET
  • PFIZER INC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record